CCS1477

CCS-1477 (CCS1477) is a potent, selective and orally bioavailable inhibitor of the Bromodomain of p300 and CBP, binding to the targets with high affinity (Kd = 1.3/1.7nM) and selectivity (Kd = 222nM; BRD4). E1A binding protein (p300) and CREB binding protein (CBP) are two closely related transcriptional activators of androgen receptor (AR) and its variant forms. CCS-1477 enhances degradation of numerous cellular proteins including the AR and AR variants in prostate cancer cells.


Cat. No.: EX-A3687	Purity: >98%

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock
100mg	700	In-stock
250mg	1200	In-stock
500mg	1600	In-stock
1g	2500	In-stock
2g	4500	In-stock
3g	5800	In-stock

Send PO to E-mail:order@excenen.com; or Fax:+86 020 81619670

Discount Request


Synonyms	Inobrodib
Synonyms 2	CCS-1477
CAS No.	2222941-37-7
Purity	>98%
Formula	C30H32F2N4O3
Mol Weight	534.5969
Appearance	solid powder
Solubility	Soluble in DMSO
Shelf Life	>2 years if stored properly
Storage	Powder -20℃ 2 years; In solvent -20℃ 1 month;
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:	[1]. Rasool RU, et al. Toppling the HAT to Treat Lethal Prostate Cancer. Cancer Discov. 2021;11(5):1011-1013. [2]. N. Pegg, et al, Characterization of CCS1477: A novel small molecule inhibitor of p300/CBP for the treatment of castration resistant prostate cancer, Journal of Clinical Oncology 2017 35:15_suppl, 11590-11590 [3]. J. S. De Bono, et al, Journal of Clinical Oncology 2019 37:15_suppl, TPS5089-TPS5089
CoA	CoA of CCS1477

Smiles:	O=C1N(C2=CC=C(F)C(F)=C2)[C@H](C3=NC4=CC(C5=C(C)ON=C5C)=CC=C4N3[C@H]6CC[C@H](OC)CC6)CCC1


		Search